Tislelizumab,Sorafenib
BeiGene,bayer,novartis
['advanced l', 'novartis']
novartis announces positive data from phase iii trial of pd-1 inhibitor in first-line advanced liver cancer #novartisnews #esmo2022
The official account for @Novartis News & Media Updates. For media inquiries: media.relations@novartis.com. See our community guidelines: https://t.co/b4Kyh4UvNm